A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis

NCT00729872 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderately Active Ulcerative Colitis

Interventions

BIOLOGICAL: AG011
OTHER: Placebo

Sponsor

ActoGeniX N.V.